A Study of IBI363 in Subjects with Advanced Solid Malignancies

Cannot have received: chemotherapy

Exception: within 2 weeks or 5 plasma half-lives prior to first dose

Any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma half-lives

Cannot have received: targeted small molecule therapy

Exception: within 2 weeks or 5 plasma half-lives prior to first dose

Any chemotherapy or targeted small molecule therapy (standard or investigational) within 2 weeks or 5 plasma half-lives

Cannot have received: nitrosoureas

Exception: within 6 weeks prior to first dose and during study

Received Nitrosoureas and mitomycin C within 6 weeks prior to first dose of study drug and during study

Cannot have received: mitomycin C (mitomycin C)

Exception: within 6 weeks prior to first dose and during study

Received Nitrosoureas and mitomycin C within 6 weeks prior to first dose of study drug and during study

Cannot have received: anti-cancer monoclonal antibody

Exception: within 4 weeks prior to first dose

Any anti-cancer monoclonal antibody (mAb) within 4 weeks prior to first dose